Mesoblast Limited vs Quantum Computing Inc — how do they compare? Mesoblast Limited trades at $16.38 (market cap $2.17B), while Quantum Computing Inc trades at $8.29 (market cap $1.79B). The key difference: Mesoblast Limited is the larger of the two by market cap, and Mesoblast Limited is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals.
| MESO | QUBT | |
|---|---|---|
Market Cap | $2.17B | $1.79B |
Sector | Technology | Technology |
52-Week High | $20.96 | $24.62 |
52-Week Low | $12.88 | $6.31 |
Enterprise Value | $2.17B | $803.83M |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Quantum Computing Inc. (QUBT) trades at $7.92, up 1.54% today, while technical indicators signal a bearish trend. The company shows minimal revenue of $682,000 for 2025 with a net loss of $18.67 million, resulting in negative profit margins. Analysts maintain a bullish consensus with a $26 price target, citing potential from commercial backlog and policy support, despite ongoing cash burn and a recent legal investigation into corporate governance.
QUBT offers high-risk, high-reward potential driven by quantum computing commercialization prospects, but faces significant execution risks and financial instability. The stock's outlook hinges on revenue scaling and managing cash flow, with substantial downside if growth targets are missed.
Trailing returns across standard periods
Latest headlines on both assets
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →